Literature DB >> 10807756

Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa.

V Ollivier1, J Chabbat, J M Herbert, J Hakim, D de Prost.   

Abstract

Tissue factor (TF) assembled with activated factor VII (FVIIa) initiates the coagulation cascade. We recently showed that TF was essential for FVIIa-induced vascular endothelial growth factor (VEGF) production by human fibroblasts. We investigated whether this production resulted from TF activation by its binding to FVIIa or from the production of clotting factors activated downstream. Incubation of fibroblasts with a plasma-derived FVIIa concentrate induced the generation of activated factor X (FXa) and thrombin and the secretion of VEGF, which was inhibited by hirudin and FXa inhibitors. By contrast, the addition of recombinant FVIIa to fibroblasts did not induce VEGF secretion unless factor X was present. Moreover, thrombin and FXa induced VEGF secretion and VEGF mRNA accumulation, which were blocked by hirudin and FXa inhibitors, respectively. The effect of thrombin was mediated by its specific receptor, protease-activated receptor-1; in contrast, the effect of FXa did not appear to involve effector cell protease receptor-1, because it was not affected by an anti-effector cell protease receptor-1 antibody. An increase in intracellular calcium with the calcium ionophore A23187 or intracellular calcium chelation by BAPTA-AM had no effect on either basal or FXa-induced VEGF secretion, suggesting that the calcium signaling pathway was not sufficient to induce VEGF secretion. Finally, FVIIa, by itself, had no effect on mitogen-activated protein (MAP) kinase activation, contrary to thrombin and FXa, which activate the p44/p42 MAP kinase pathway, as shown by the blocking effect of PD 98059 and by Western blotting of activated MAP kinases. These findings indicate that FVIIa protease induction of VEGF expression is mediated by thrombin and FXa generated in response to FVIIa binding to TF-expressing fibroblasts; they also exclude a direct signaling involving MAP kinase activation via the intracellular domain of TF when expressed by these cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807756     DOI: 10.1161/01.atv.20.5.1374

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

Review 1.  Platelets: linking hemostasis and cancer.

Authors:  Shashank Jain; John Harris; Jerry Ware
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 2.  The hemostatic system and angiogenesis in malignancy.

Authors:  M Z Wojtukiewicz; E Sierko; P Klement; J Rak
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

3.  An engineered muscle flap for reconstruction of large soft tissue defects.

Authors:  Yulia Shandalov; Dana Egozi; Jacob Koffler; Dekel Dado-Rosenfeld; David Ben-Shimol; Alina Freiman; Erez Shor; Aviva Kabala; Shulamit Levenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

4.  Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.

Authors:  Eric T Alexander; Allyson R Minton; Candace S Hayes; Ashley Goss; Joanne Van Ryn; Susan K Gilmour
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  IFATS collection: Adipose-derived stromal cells improve the foreign body response.

Authors:  Heather L Prichard; William Reichert; Bruce Klitzman
Journal:  Stem Cells       Date:  2008-04-24       Impact factor: 6.277

Review 6.  Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  J Mol Med (Berl)       Date:  2013-08-17       Impact factor: 4.599

Review 7.  Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View.

Authors:  Elżbieta Zarychta; Barbara Ruszkowska-Ciastek
Journal:  Biomedicines       Date:  2022-01-27

Review 8.  Extracellular vesicles in prostate cancer: new future clinical strategies?

Authors:  Ilaria Giusti; Vincenza Dolo
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.